CTIM-07. IDENTIFICATION OF A BASELINE BIOMARKER ASSOCIATED WITH TUMOR RESPONSES IN A PHASE I/IIa TRIAL OF A THERAPEUTIC CMV VACCINE AGAINST RECURRENT GLIOBLASTOMA (GBM)

Cytomegalovirus (CMV) antigens have been reported in over 90% of GBM tumors. CD4(+) and CD8(+) T cells are most frequently directed against the gB and pp65 antigens, respectively, and are immunogenic targets in a CMV-based GBM vaccine. We enrolled 10 patients (6 women, 4 men) with KPS at least 70 an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Wen, Patrick, Reardon, David, Forst, Deborah, Lee, Eudocia, Iwamoto, Fabio, Diaz-Mitoma, Francisco, Anderson, David, Lassman, Andrew
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Trials: Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650406/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.141
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados